Artugen Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

Artugen Therapeutics General Information

Description

Provider of clinical research and development services intended to focus on the development of an antimicrobial agent. The company's services through its antimicrobial agent can kill the Clostridium Difficile bacterium, which is resistant to antibiotics, enabling clients to receive a drug that can act as a preventative treatment against Clostridium Difficile.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 530 Virginia Road
  • Suite 300
  • Concord, MA 01742
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 530 Virginia Road
  • Suite 300
  • Concord, MA 01742
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Artugen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 10-Mar-2022 Completed Generating Revenue
6. Early Stage VC (Series B) 31-Dec-2021 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 28-Jan-2020 Completed Clinical Trials - Phase 1
4. Early Stage VC 28-Jun-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 29-Oct-2018 Completed Clinical Trials - Phase 1
2. Early Stage VC 30-Nov-2017 $1.03M $2.6M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 20-May-2016 $1.57M $1.57M Completed Clinical Trials - Phase 1
To view Artugen Therapeutics’s complete valuation and funding history, request access »

Artugen Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series B
Series B
Series A
Series A
Series A 19,511,074 $0.000100 $0.04 $0.04 1x $0.04 3.25%
Series A 1,500,000 $0.000100 $0.92 $0.92 1x $0.92 0.25%
To view Artugen Therapeutics’s complete cap table history, request access »

Artugen Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Artugen Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Morningside Group Venture Capital Minority
To view Artugen Therapeutics’s complete investors history, request access »

Artugen Therapeutics FAQs

  • When was Artugen Therapeutics founded?

    Artugen Therapeutics was founded in 2015.

  • Where is Artugen Therapeutics headquartered?

    Artugen Therapeutics is headquartered in Concord, MA.

  • What is the size of Artugen Therapeutics?

    Artugen Therapeutics has 10 total employees.

  • What industry is Artugen Therapeutics in?

    Artugen Therapeutics’s primary industry is Drug Discovery.

  • Is Artugen Therapeutics a private or public company?

    Artugen Therapeutics is a Private company.

  • What is Artugen Therapeutics’s current revenue?

    The current revenue for Artugen Therapeutics is .

  • How much funding has Artugen Therapeutics raised over time?

    Artugen Therapeutics has raised $32.9M.

  • Who are Artugen Therapeutics’s investors?

    Morningside Group has invested in Artugen Therapeutics.

  • When was Artugen Therapeutics acquired?

    Artugen Therapeutics was acquired on 10-Mar-2022.

  • Who acquired Artugen Therapeutics?

    Artugen Therapeutics was acquired by Adiso Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process